X @None

Moderna shares more than doubled after its personalized cancer vaccine cleared a late-stage melanoma trialThe shot, intismeran, is tailored to mutations in each patient's tumor and was tested alongside Merck's Keytruda. Patients on the combination went longer without the cancer returning or spreading than those on Keytruda alone.The treatment is not approved and @moderna_tx released initial results only. $MRNA traded at $158.29 against a previous close of $62.96, with short sellers facing about $5B in losse ...